title: Adoptive immunotherapy of cancer: biological response modifiers and cytotoxic cell therapy.
abstract: Immunotherapy has been developed for the treatment of metastatic cancers refractory to conventional therapies. Immunotherapy utilizes immune cells and/or biological response modifiers (BRMs) to induce an anti-tumor response mediated by the patient's immune system. BRMs, including lymphokines and cytokines, are used as single agents or in combination for cancer therapy. Some BRMs, particularly interleukin 2 (IL-2), can activate and expand in vitro lymphocytes with anti-tumor reactivity which will be adoptively transferred to the patient. To enhance the therapeutic effect of immunotherapy, gene therapy is currently under investigation and involves the insertion of cytokine genes in immune cells or in tumor cells. The development and future of cancer immunotherapy will be discussed in this review.
authors.affiliation: Department of Urology, Wayne State University, Detroit, MI 48201.
authors.forename: G G
authors.initials: GG
authors.lastname: Hillman
authors.forename: G P
authors.initials: GP
authors.lastname: Haas
authors.forename: W H
authors.initials: WH
authors.lastname: Wahl
authors.forename: D M
authors.initials: DM
authors.lastname: Callewaert
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors